The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?

被引:144
作者
Cillo, U
Bassanello, M
Vitale, A
Grigoletto, FA
Burra, P
Fagiuoli, S
D'Amico, F
Ciarleglio, FA
Boccagni, P
Brolese, A
Zanus, G
D'Amico, DF
机构
[1] Univ Padua, Sch Med, Dipartimento Sci Chirurg & Gastroenterol, Clin Chirurg 1, I-35128 Padua, Italy
[2] Univ Padua, Sch Med, Dipartimento Med Ambientale & Sanita Pubbl, Unita Biostat & Epidemiol, I-35128 Padua, Italy
[3] Univ Padua, Sch Med, Dipartimento Sci Chirurg & Gastroenterol, Div Gastroenterol, I-35128 Padua, Italy
关键词
hepatocellular carcinoma; prognosis; staging; therapeutic decision; tumor stage; liver function;
D O I
10.1016/j.jhep.2003.09.027
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Prognosis assessment in patients with hepatocellular carcinoma (HCC remains controversial. The most widely used HCC prognostic tool is the Okuda classification, but new staging systems (Cancer of the Liver Italian Program score, Chinese University Prognostic Index, French classification and Barcelona Clinic Liver Cancer, BCLC, staging) have been recently described. We investigated the value of known prognostic systems in the particular setting of a surgically oriented Liver Unit where 187 HCC Italian patients were mainly treated with radical therapies (resection and percutaneous ablation). Methods: A retrospective analysis of 187 HCCs observed at a single Institution from 1990 and 1999 was performed. By using survival time as the only outcome measure (Kaplan-Meier method and Cox regression), the performance of any prognostic system was assessed according the criteria of discriminatory and stratification abilities between different stages, homogeneity of survival within each stage and additional explanatory power respect to the other classifications. Results: In the particular cohort studied, BCLC proved the best HCC prognostic system. This was true for the whole study group and for the 2 subgroups of surgical and non-surgical patients. Conclusions: BCLC staging showed the best interpretation of the survival distribution in an HCC population comprising a large proportion of tumors treated with potentially radical therapies. (C) 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:124 / 131
页数:8
相关论文
共 35 条
[1]  
[Anonymous], 1997, AJCC CANC STAGING MA
[2]   Hepatocellular carcinoma: Diagnosis and treatment [J].
Befeler, AS ;
Di Bisceglie, AM .
GASTROENTEROLOGY, 2002, 122 (06) :1609-1619
[3]   Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis [J].
Bolondi, L ;
Sofia, S ;
Siringo, S ;
Gaiani, S ;
Casali, A ;
Zironi, G ;
Piscaglia, F ;
Gramantieri, L ;
Zanetti, M ;
Sherman, M .
GUT, 2001, 48 (02) :251-259
[4]   Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure [J].
Bruix, J ;
Castells, A ;
Bosch, J ;
Feu, F ;
Fuster, J ;
GarciaPagan, JC ;
Visa, J ;
Bru, C ;
Rodes, J .
GASTROENTEROLOGY, 1996, 111 (04) :1018-1022
[5]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[6]   Prognostic prediction and treatment strategy in hepatocellular carcinoma [J].
Bruix, J ;
Llovet, JM .
HEPATOLOGY, 2002, 35 (03) :519-524
[7]   A new prognostic classification for predicting survival in patients with hepatocellular carcinoma [J].
Chevret, S ;
Trinchet, JC ;
Mathieu, D ;
Rached, AA ;
Beaugrand, M ;
Chastang, C .
JOURNAL OF HEPATOLOGY, 1999, 31 (01) :133-141
[8]   HEPATOCELLULAR-CARCINOMA IN ITALIAN PATIENTS WITH CIRRHOSIS [J].
COLOMBO, M ;
DEFRANCHIS, R ;
DELNINNO, E ;
SANGIOVANNI, A ;
DEFAZIO, C ;
TOMMASINI, M ;
DONATO, MF ;
PIVA, A ;
DICARLO, V ;
DIOGUARDI, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (10) :675-680
[9]   Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[10]  
Farinati F, 2000, CANCER, V89, P2266, DOI 10.1002/1097-0142(20001201)89:11<2266::AID-CNCR15>3.3.CO